- Home
- UBFO vs ZURA Comparison
UBFO vs ZURA Comparison
Compare UBFO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- ZURA
- Stock Information
- Founded
- UBFO 1987
- ZURA 2022
- Country
- UBFO United States
- ZURA United States
- Employees
- UBFO N/A
- ZURA N/A
- Industry
- UBFO Major Banks
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UBFO Finance
- ZURA Health Care
- Exchange
- UBFO Nasdaq
- ZURA Nasdaq
- Market Cap
- UBFO 154.8M
- ZURA 137.2M
- IPO Year
- UBFO N/A
- ZURA N/A
- Fundamental
- Price
- UBFO $9.27
- ZURA $4.02
- Analyst Decision
- UBFO
- ZURA Buy
- Analyst Count
- UBFO 0
- ZURA 9
- Target Price
- UBFO N/A
- ZURA $11.00
- AVG Volume (30 Days)
- UBFO 24.1K
- ZURA 3.9M
- Earning Date
- UBFO 10-17-2025
- ZURA 11-06-2025
- Dividend Yield
- UBFO 5.19%
- ZURA N/A
- EPS Growth
- UBFO N/A
- ZURA N/A
- EPS
- UBFO 0.65
- ZURA N/A
- Revenue
- UBFO $44,636,000.00
- ZURA N/A
- Revenue This Year
- UBFO N/A
- ZURA N/A
- Revenue Next Year
- UBFO N/A
- ZURA N/A
- P/E Ratio
- UBFO $14.13
- ZURA N/A
- Revenue Growth
- UBFO N/A
- ZURA N/A
- 52 Week Low
- UBFO $7.32
- ZURA $0.97
- 52 Week High
- UBFO $10.49
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- UBFO 45.71
- ZURA 76.13
- Support Level
- UBFO $9.05
- ZURA $3.57
- Resistance Level
- UBFO $9.53
- ZURA $4.21
- Average True Range (ATR)
- UBFO 0.25
- ZURA 0.43
- MACD
- UBFO -0.07
- ZURA 0.20
- Stochastic Oscillator
- UBFO 25.58
- ZURA 82.67
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.